Table 2.
Summary of the effect of ZOL treatment on clinical outcomes. Data are presented as number of events / number of patients in each group followed by hazard ratio and 95% confidence interval
| Recurrence | Bone Recurrence | Non-Bone Recurrence | Breast Cancer Survival | Overall Survival | |
|---|---|---|---|---|---|
| Age < 45, ER+/HER2− |
ZOL: 5/8 No ZOL: 3/14 HR 6.05 [1.26–29.1] |
ZOL: 4/8 No ZOL: 2/14 HR 6.01 [0.97–37.1] |
ZOL: 5/8 No ZOL: 2/14 HR 6.94 [1.26–38.1] |
ZOL: 3/8 No ZOL: 2/14 HR 4.43 [0.62–31.7] |
ZOL: 3/8 No ZOL: 2/14 HR 4.43 [0.62–31.7] |
| Age >= 45, ER+/HER2− | ZOL: 9/18 No ZOL: 5/15 HR 1.95 [0.57–6.66] |
ZOL: 3/18 No ZOL: 5/15 HR 0.78 [0.16–3.83] |
ZOL: 8/18 No ZOL: 5/15 HR 1.53 [0.44–5.30] |
ZOL: 8/18 No ZOL: 3/15 HR 2.71 [0.54–13.6] |
ZOL: 9/18 No ZOL: 4/15 HR 2.13 [0.54–8.31] |
| Age 45–54, ER+/HER2− | ZOL: 5/10 No ZOL: 3/9 HR 3.12 [0.51–19.0] |
ZOL: 2/10 No ZOL: 3/9 HR 1.68 [0.15–18.9] |
ZOL: 5/10 No ZOL: 3/9 HR 2.62 [0.46–15.0] |
ZOL: 4/10 No ZOL: 1/9 HR 2.79 [0.19–40.8] |
ZOL: 5/10 No ZOL: 2/9 HR 2.10 [0.30–14.9] |
| Age < 45, Triple-Negative | ZOL: 3/7 No ZOL: 3/5 HR 0.89 [0.12–6.59] |
ZOL: 2/7 No ZOL: 1/5 HR 0.49 [0.03–7.94] |
ZOL: 3/7 No ZOL: 3/5 HR 0.89 [0.12–6.59] |
ZOL: 2/7 No ZOL: 4/6 HR 0.31 [0.03–3.11] |
ZOL: 2/7 No ZOL: 4/6 HR 0.31 [0.03–3.11] |
| Age >= 45, Triple-Negative | ZOL: 6/13 No ZOL: 6/11 HR 0.53 [0.17–1.72] |
ZOL: 2/13 No ZOL: 2/11 HR 0.54 [0.07–4.03] |
ZOL: 5/13 No ZOL: 5/11 HR 0.47 [0.13–1.72] |
ZOL: 5/13 No ZOL: 5/11 HR 0.53 [0.15–1.89] |
ZOL: 6/13 No ZOL: 6/11 HR 0.52 [0.16–1.66] |